CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies.

ABSTRACT: The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint immunotherapy. Inherent in any T cell response to a tumor antigen is the capacity of dendritic cells to initiate and support such responses. Here, the rationale and early immunobiology of CD40 as a master regulator of dendritic cell activation is reviewed, with further contextualization and appreciation for the role of CD40 stimulation not only in cancer vaccines but also in other contemporary immune-oncology approaches.

SUBMITTER: Bullock TNJ 

PROVIDER: S-EPMC8752810 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature